NeoTherma Oncology news
NeoTherma Oncology (NTO) announces they have expanded their leadership team with key senior staff who will advance the development and commercialization of the VectRx System. NTO’s new additions include:
- Ken Belt, Chief Engineer: Ken will lead RF design, and has 48 years of experience in the medical device field with extensive experience in MRI coil and phased array engineering.
- Lawson Fisher
Neotherma Oncology (NTO) announces the appointment of Bob Larson as Chief Executive Officer effective immediately. Bob is an experienced health care executive with 30+ years spread across the medical device, bio-pharmaceutical, and tech industries. He has held senior leadership positions at companies ranging from startups to Fortune 500 multi-nationals such as Johnson & Johnson and Zoetis.
NeoTherma Oncology, having achieved both FDA approval for its Investigational Device Exemption for an Early Feasibility Study of the VectRx™ System and institutional review board approval at an east coast National Cancer Institute-designated Cancer Center, has initiated recruitment for a first-in-human trial in patients with pancreatic cancer.
NeoTherma Oncology, (NTO) a privately held medical device company developing novel non-invasive treatments for solid tumors, today announces they have submitted an Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) to initiate First-in-Human (FiH) studies of the VectRx™ System in patients with pancreatic cancer being treated with standard of care chemotherapy under the Early Feasibility Study (EFS) Guidance. Previously granted `Breakthrough Tech